Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amikacin inhalation - Nektar Therapeutics

Drug Profile

Amikacin inhalation - Nektar Therapeutics

Alternative Names: Aerosolised amikacin; Amikacin inhale; BAY-416551; Inhaled amikacin; NKTR-061

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Bayer HealthCare; Nektar Therapeutics
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gram-negative infections; Ventilator associated pneumonia

Most Recent Events

  • 13 Jan 2018 Bayer terminates its licence for inhaled amikacin
  • 07 Apr 2017 Bayer completes the phase III INHALE 2 trial in Gram-negative infections and Ventilator-associated-pneumonia in Belgium, China, France, Germany, Greece, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Portugal, Russia, Spain, Ukraine, Czech Republic, Latvia (NCT00805168)
  • 06 Apr 2017 Bayer completes the phase III INHALE 1 trial in Gram-negative infections and Ventilator-associated-pneumonia in USA, Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, South Korea, Mexico, Philippines, Taiwan, Thailand, Turkey (NCT01799993)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top